Left Ventricular Assist Device Infections and the Potential Role for Dalbavancin: A Case Report

Jessica Howard-Anderson; Stephanie M Pouch; Mary Elizabeth Sexton; Aneesh K Mehta; Andrew L Smith; George M Lyon 3rd; Rachel Friedman-Moraco

doi:10.1093/ofid/ofz235

Left Ventricular Assist Device Infections and the Potential Role for Dalbavancin: A Case Report

Open Forum Infect Dis. 2019 Sep 4;6(9):ofz235. doi: 10.1093/ofid/ofz235. eCollection 2019 Sep.

Authors

Jessica Howard-Anderson¹, Stephanie M Pouch¹, Mary Elizabeth Sexton¹, Aneesh K Mehta¹, Andrew L Smith², George M Lyon 3rd¹, Rachel Friedman-Moraco¹

Affiliations

¹ Division of Infectious Diseases, Atlanta, Georgia.
² Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia.

Abstract

Left ventricular assist device infections (LVADIs) are common but challenging to treat, often requiring prolonged courses of intravenous antibiotics. Dalbavancin could have a role in treating patients with chronic LVADIs given its less frequent dosing requirements. Here, we illustrate a case in which dalbavancin was used as suppressive therapy for an LVADI for greater than 7 months.

Keywords: Staphylococcus aureus; dalbavancin; left ventricular assist devices.

Publication types

Case Reports